Signing of Strategic Platform Licence

RNS Number : 6449Z
MaxCyte, Inc.
25 May 2021





Celularity and MaxCyte Sign Strategic Platform Licence

to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates


Celularity to utilize MaxCyte's Flow Electroporation ® technology and ExPERTplatform to advance its  off-the-shelf placental-derived allogeneic cellular therapies to treat hematological malignancies, solid tumours, and infectious and degenerative diseases


FLORHAM PARK, NJ, and GAITHERSBURG, MD, 25 May 2021 - Celularity, Inc. ("Celularity"), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic platform licence.


Celularity will obtain non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform enabling Celularity to accelerate the development of innovative, off the shelf allogeneic cell therapies, including genetically modified natural killer (NK) cell therapies and CAR T-cell therapies derived from the postpartum placenta. In return, MaxCyte is entitled to platform licensing fees and programme-related milestone payments.


"This strategic relationship provides Celularity with access to MaxCyte's unique electroporation technology platform, representing an important enabling step in allogeneic cell therapy. We expect to leverage this transaction and our new state-of-the-art manufacturing facility to advance the delivery of best-in-class cell therapies to patients with unmet medical needs," said Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity. "We are very excited to be working with MaxCyte, an established leader in cell engineering."

Doug Doerfler, President & CEO of MaxCyte, said: "Celularity's approach to developing new immunotherapies to treat cancer and other diseases appears very promising. The company is leading the next evolution in cellular medicine by leveraging a novel cell source, and we are very proud the team has selected MaxCyte's technology to help enable this important work."

MaxCyte's ExPERT™ instrument portfolio represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.


About Celularity


Celularity , headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placenta -derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells ( ASCs ) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta's unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

In January 2021, Celularity entered into a definitive merger agreement with GX Acquisition Corp. ("GX") to create a publicly listed leader in allogeneic cellular therapy. GX is listed on Nasdaq under the ticker symbol "GXGX." Upon closing of the business combination (the "Business Combination"), expected to be completed in the second quarter of 2021, shares of the combined company will be listed on Nasdaq under the ticker symbol "CELU."


To learn more, visit .


About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies that are driving the next‐generation of cell-based therapies and making a meaningful difference for patients. The Company's technology is employed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte has granted 13 strategic platform licences to leading cell-based therapy developers. Through 2020, MaxCyte has granted licences for more than 140 cell therapy programmes, with over 100 licences for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit .


About GX


GX is a blank check company incorporated in Delaware for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. GX is led by Jay R. Bloom and Dean C. Kehler, who serve as Managing Partners of Trimaran Capital Partners.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.




Celularity Contacts


For Investors

Carlos Ramirez
Celularity Inc.  


Alexandra Roy
Solebury Trout  


For Media

Jason Braco, Ph.D.

LifeSci Communications

+1 646 751-4361


GX Contact

Caroline Luz

Lambert & Co.  


MaxCyte Contacts


MaxCyte Inc.     + 1 301 944 1660

Doug Doerfler, President and Chief Executive Officer

Amanda Murphy, Chief Financial Officer


Nominated Adviser and Joint Corporate Broker   +44 (0)20 7886 2500

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden


Joint Corporate Broker  

Numis Securities Limited  +44 (0)20 7260 1000

James Black / Duncan Monteith / Matthew O'Dowd


Joint Corporate Broker

Stifel Nicolaus Europe Limited    +44 (0) 20 7710 7600

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams


Financial PR Adviser  + 44 (0)203 709 5700

Consilium Strategic Communications    maxcyte@consilium‐

Mary-Jane Elliott

Chris Welsh




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings